AUS
NZ
UK
CA
USA
IND
Highlights
- Market Cap stands at $21.77 billion for Biogen Inc.
- 52-week range between $145.07 and $268.30.
- Current ratios: Quick ratio of 0.80 and current ratio of 1.26.
Biogen Inc. (NASDAQ:BIIB) operates within the biotechnology sector, focusing on the development and commercialization of therapies for neurological and neurodegenerative diseases. The sector is characterized by significant research and development activities, aiming to innovate treatments for complex medical conditions.
Market Performance Metrics
NASDAQ-listed Biogen Inc. opened at $149.38 on Tuesday. The company boasts a market capitalization of $21.77 billion, reflecting its substantial presence in the biotechnology industry. The price-to-earnings (PE) ratio stands at 13.49, providing insight into the company's valuation relative to its earnings.
Growth Indicators
The price-to-earnings-growth (P/E/G) ratio for Biogen is recorded at 1.83. This metric offers a perspective on the company's valuation by considering its earnings growth rate. Additionally, Biogen exhibits a beta of -0.08, indicating its stock's volatility in relation to the broader market movements.
Moving Averages
Biogen's 50-day moving average price is $167.48, while the 200-day moving average price is $195.31. These moving averages are utilized to assess the stock's trend over different time frames, providing a benchmark for its recent performance against longer-term trends.
Liquidity Ratios
The company's debt-to-equity ratio is 0.28, which measures the proportion of debt financing relative to shareholders' equity. A lower ratio suggests a more conservative capital structure with less reliance on debt. Biogen also maintains a quick ratio of 0.80 and a current ratio of 1.26, indicating its ability to meet short-term obligations with its most liquid assets.
52-Week Price Range
Over the past year, Biogen's stock has experienced a 52-week low of $145.07 and a 52-week high of $268.30. This range highlights the stock's price fluctuations and provides a context for its current trading position within the year.
Financial Stability
Biogen's financial metrics reflect its stability within the competitive biotechnology sector. The company's ability to manage its debt and maintain liquidity ratios above industry averages demonstrates its capacity to sustain operations and support ongoing research initiatives.
Biogen Inc. remains a significant player in the biotechnology sector, with robust financial metrics and a stable market presence. The company's performance indicators provide a comprehensive view of its financial health and operational standing within the industry.
